Soleno Therapeutics Announces Retirement of James Mackaness and Appointment of Jennifer Fulk as Chief Financial Officer

Core Viewpoint - Soleno Therapeutics, Inc. has appointed Jennifer Fulk as the new Chief Financial Officer, succeeding James Mackaness, who is retiring. This leadership change is expected to support the company's ongoing efforts in developing treatments for rare diseases, particularly Prader-Willi syndrome, while maintaining financial discipline and driving long-term value [1][2][3]. Group 1: Leadership Transition - Jennifer Fulk has over 20 years of experience in public company financial strategy, investor relations, and operational efficiency, including 15 years at Eli Lilly [1][3]. - James Mackaness will assist as a consultant until the end of the year to ensure a smooth transition [1][2]. Group 2: Company Focus and Product Development - Soleno is focused on developing and commercializing novel therapeutics for rare diseases, with its first product, VYKAT™ XR, approved by the FDA on March 26, 2025 [4]. - VYKAT™ XR is a once-daily oral treatment for hyperphagia in individuals aged 4 and older with Prader-Willi syndrome [4]. Group 3: Executive Insights - Dr. Anish Bhatnagar, CEO, expressed confidence in Fulk's ability to enhance the company's financial foundation and support the rollout of VYKAT™ XR in the U.S. and its regulatory approval in the EU [2][3]. - Fulk emphasized her excitement about joining Soleno and contributing to the mission of providing new treatment options for patients with rare diseases [3].